Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Hematology & Oncology|April 23, 2025
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meetingV Tomarchio, L Rigacci, O AnnibaliLeukemia Research|February 12, 2018
PD-1 /PD-L1 checkpoint in hematological malignanciesO Annibali, A Crescenzi, V Tomarchio, et al.International Journal of Hematology-Oncology and Stem Cell Research|January 18, 2018
Protective Isolation for Patients with Haematological Malignancies: A Pilot Study Investigating Patients' Distress and Use of TimeO Annibali, C Pensieri, V Tomarchio, et al.Journal of Chemotherapy (Florence, Italy)|April 1, 2026
Cytofluorimetric study of cerebrospinal fluid at staging of diffuse large B cell lymphomaO Annibali, C Bancone, V Tomarchio, et al.Journal of Clinical and Experimental Hematopathology : JCEH|June 19, 2012
Tuberculous meningoencephalitis in a patient with hairy cell leukemia in complete remissionK Girardi, A Paviglianiti, M Cirillo, et al.Annals of Hematology|February 2, 2021
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio groupFederico Vozella, A Siniscalchi, M Rizzo, et al.Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.Journal of Bone Oncology|December 11, 2020
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?O Annibali, M T Petrucci, D Santini, et al.Pageof 1